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Background: The main transmission route of the hepatitis B virus (HBV) is mother to child transmission and
contributes significantly to chronic HBV infection. Even though immunoprophylaxis with hepatitis B
immunoglobulin (HBIG) and hepatitis B vaccine is administrated to neonates whose mothers are hepatitis B surface
antigen (HBsAg) positive, about 10% of the neonates suffer from HBV infection in their early life.
Objectives: To survey chronic HBV infection among pregnant women and their infants and analyze the reason for
immunoprophylaxis failure.
Methods: Serum HBsAg was tested in all pregnant women. HBVDNA and other serum HBV markers including
hepatitis B e antigen (HBeAg), hepatitis B core antibody (anti-HBc) and hepatitis B surface antibody (anti-HBs) were
tested among HBsAg positive pregnant women. All infants whose mothers were HBsAg positive were vaccinated
with a standard immunoprophylaxis. Serum HBV markers and HBVDNA were tested among these infants at 7
months of age. HBV genotypes were analyzed among the infants and pregnant women who were HBVDNA
positive.
Results: The prevalence of HBsAg, anti-HBc and anti-HBs among 4,536 pregnant women was 5.49%, 29.65% and
58.55%, respectively. The prevalence of HBsAg, anti-HBc and anti-HBs among pregnant women older than 20 years
of age was significantly different compared to pregnant women younger than 20 years of age (4.54, 5.69 and 0.61
times, prevalence older vs. younger, respectively. P<0.05, 0.01, 0.05, respectively). Among 249 HBsAg positive
pregnant women, 167 (67.07%) were HBeAg positive, 204 (81.93%) were HBVDNA positive and only 37 (14.86%) had
HBVDNA >107 IU/ml. Among the infants whose mothers were HBsAg positive, 214 (85.94%) infants were anti-HBs
positive. There were 12 (4.82%) infants who were HBsAg and HBVDNA positive, and all 12 of these infants mothers
were HBeAg positive and had HBVDNA >107 IU/ml. Genotypes B and C were present among 165 pregnant women
and genotype C was present in 85 pregnant women. There were 12 infants who were HBsAg positive and had the
same HBV genotypes as their mothers. There was a significant difference in genotypes between the pregnant
women whose infants were infected with HBV compared to those without HBV infection (P < 0.05).
Conclusions: There was a significant decline in HBsAg prevalence among pregnant women and their infants in
Shenyang. Genotype C might be a risk factor for mother to child transmission of HBV.
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Worldwide, there are about 350 million people with
chronic hepatitis B virus (HBV) infection and about one
million deaths per year due to chronic hepatitis, cirrho-
sis, and hepatocellular carcinoma [1,2]. Mother to child
transmission of HBV is the main transmission route and
contributes significantly to chronic HBV infection [3].
China used to be an area of HBV high epidemicity.
About 10% of infants whose mothers were HBV positive
suffered from HBV infection in their early life. It has
been reported that the prevalence of Hepatitis B surface
antigen (HBsAg) has been reduced from 9.75% in 1992
to 7.18% in 2006 [4]. In our study, we aimed to survey
chronic HBV infection among pregnant women and
their infants in Shenyang, China and analyze the reason
for immunoprophylaxis failure.Subjects and methods
Between June 2010 and November 2011, all pregnant
women who delivered at Shengjing Hospital of China
Medical University were enrolled. Because immunopro-
phylaxis with hepatitis B immunoglobulin (HBIG) and
hepatitis B vaccine has been universally administrated in
Shenyang since 1990, the pregnant women were divided
into two age groups: younger than 20 years and older
than 20 years of age. Serum HBsAg was tested in all
pregnant women. HBVDNA and other serum HBV mar-
kers including hepatitis B e antigen (HBeAg), hepatitis B
core antibody (anti-HBc) and hepatitis B surface anti-
body (anti-HBs) were tested among HBsAg positive
pregnant women.
All infants whose mothers were HBsAg positive were
vaccinated with hepatitis B vaccine 20 ug (Changchun
Biotech Research Institute, Changchun, China) accord-
ing to a standard vaccination regimen (within 12 h of
birth, at week 4, and week 24) and 200 IU doses of
HBIG (Hualan Biotech Research Institute, Xinxiang,
China) immediately (within 2 h of birth) and at day 15.Table 1 The prevalence of HBsAg, anti-HBc and anti-HBs amo
Age group HBsAg OR
Positive Negative Posit
less than 20 years old 2 152 1.0@ 11
n=154 (1.30%) (98.70%) (7.14
older than 20 years 247 4135 4.54 133
n=4382 (5.64%) (94.36%) (30.44
total 249 4287 134
n=4536 (5.49%) (94.51%) (29.65
X2 4.59
P < 0.05
@-reference category.These infants were followed up at 7 months of age. Serum
HBV markers and HBVDNA were tested. HBV genotypes
were tested among the infants and pregnant women who
were HBVDNA positive.
HBV markers were quantitatively assayed with a chemi-
luminescent microparticle immunoassay using an auto-
mated Abbott AxSYM analyser (Abbott, USA). HBsAg
below 0.05 IU/ml, anti-HBs below 10.0 mIU/ml, HBeAg
and anti-HBc below the signal/cutoff ratio of 1.0 were
considered negative. HBVDNA was analyzed using a
real-time PCR assay using COBAS AmpliPrep/COBAS
TaqMan 48 analyser (Roche, Switzerland), HBVDNA<12
IU/ml was considered negative. HBV genotypes were ana-
lyzed using the TRUGENE HBV genotyping kit (Siemens
medical solutions diagnostics, Saint Denis, France).
Statistical analysis was performed using the Statistical
Package for the Social Sciences (version 17.0, SPSS,
Chicago, IL, USA). Data were analyzed by Fisher’s exact
test and calculated odds ratio (OR) value and 95% confi-
dence interval (CI). Statistically significant differences
were defined as P<0.05.
Results
The prevalence of HBsAg, anti-HBc and anti-HBs among
pregnant women
A total of 4,536 pregnant women aged 16 – 45 years
were screened for HBsAg. The prevalence of HBsAg
among pregnant women was 5.49% (249/4536). The
prevalence of HBsAg among pregnant women older than
20 years (5.64%) was 4.54 times that among pregnant
women younger than 20 years (1.30%) (OR = 4.54, 95%
CI: 1.12~18.43). This higher prevalence of HBsAg
among pregnant women older than 20 years was signifi-
cant higher compared to pregnant women younger than
20 years (P < 0.05) (Table 1).
The prevalence of anti-HBc among pregnant women
was 29.65% (1345/4536). The prevalence of anti-HBc
among pregnant women older than 20 years (30.44%) was
5.69 times that among pregnant women younger than 20ng pregnant women in the different age groups
anti-HBc OR anti-HBs OR
ive Negative Positive Negative
143 1.0@ 107 47 1.0@
%) (92.86%) (69.48%) (30.54%)
4 3048 5.69 2549 1833 0.61
%) (69.56%) (58.17%) (41.83%)
5 3191 2656 1880
%) (70.35%) (58.55%) (41.45%)
37.61 7.38
< 0.01 < 0.05
Table 2 HBeAg status and HBVDNA load among HBsAg
positive pregnant women
HBVDNA HBeAg positive HBeAg negative Total
IU/ml n=167 n=82 n=249
<12 0(0%) 45(54.88%) 45(18.07%)
(12–50) 2(1.20%) 9(39.02%) 11(4.42%)
(50-<107) 128(76.64%) 28(6.10%) 156(62.65%)
(>107) 37(22.16%) 0(0%) 37(14.86%)
Ding et al. Virology Journal 2013, 10:17 Page 3 of 5
http://www.virologyj.com/content/10/1/17years (7.14%) (OR = 5.69, 95%CI: 3.07~10.54). This higher
prevalence of anti-HBc among pregnant women older
than 20 years was significant higher compared to pregnant
women younger than 20 years (P < 0.01) (Table 1).
The prevalence of anti-HBs among pregnant women
was 58.55% (2656/4536). The prevalence of anti-HBs
among pregnant women older than 20 years (58.17%) was
0.61 times that among pregnant women younger than 20
years (69.48%) (OR = 0.61, 95%CI: 0.43~0.87). This lower
prevalence of anti-HBs among pregnant women older
than 20 years was significant lower compared to pregnant
women younger than 20 years (P < 0.05) (Table 1).HBeAg status and HBVDNA load among HBsAg positive
pregnant women
HBeAg and HBVDNA were analyzed among the 249
HBsAg positive pregnant women. Of the 249 women, 167
(67.07%) were HBeAg positive and 204 (81.93%) were
HBVDNA positive. Of the 204 HBVDNA positive women,
only 37 (14.86%) had HBVDNA >107 IU/ml. All pregnant
women with HBVDNA >107 IU/ml were HBeAg positive
and all those who were HBVDNA negative were HBeAg
negative (Table 2).Table 3 Serological and virological profile for the 12 infected
No. Mothers
HBsAg HBeAg anti-HBc anti-HBs HBVDNA (IU/ml)
1 + + + - 5.56×107
2 + + + - 5.49×108
3 + + + - 2.37×108
4 + + + - 4.12×108
5 + + + - 2.89×109
6 + + + - 2.16×107
7 + + + - 2.63×108
8 + + + - 2.03×108
9 + + + - 6.61×107
10 + + + - 7.17×107
11 + + + - 1.93×107
12 + + + - 2.59×107HBV infection of infants
There were 249 infants whose mothers were HBsAg
positive and were vaccinated with standard immunopro-
phylaxis and followed up at 7 months of age. There were
214 (85.94%) infants who tested anti-HBs positive only.
There were 12 (4.82%) infants who were HBsAg and
HBVDNA positive, and their mothers were HBeAg posi-
tive and HBVDNA >107 IU/ml (Table 3). There were 2
(16.67%) infants who were anti-HBs positive among the
12 HBsAg positive infants.The anti-HBs titers were
547.25 mIU/ml and 1224.58 mIU/ml, respectively.
HBV genotypes among pregnant women and their infants
Only genotypes B and C had been found among 165
pregnant women (Table 4). The 165 pregnant women
were divided into two groups on the basis of their
infants being with or without HBV infection. There were
12 infants who were HBsAg positive and had the same
HBV genotypes as their mothers. Genotype C was
present in 85 pregnant women. Genotype C was present
in 10 pregnant women whose infants were infected with
HBV and 75 pregnant women whose infants were not
infected with HBV. Genotype B was present in 2 preg-
nant women whose infants were infected with HBV.
There was a significant difference between pregnant
women whose infants were infected with HBV and those
without HBV infection (P=0.04 < 0.05). Genotype C was
present in 2 anti-HBs and HBsAg positive infants.
Discussions
There are more than 130 million chronic HBV carriers in
China, 30%-50% of whom are thought to have acquired
HBV infection from mother-to-child transmission [5-7].
Preventing the mother-to-child transmission route can
significantly decrease HBV infection among infants andmother-infant pairs
Infants
HBsAg HBeAg anti-HBc anti-HBs HBVDNA (IU/ml)
+ + + - 1.14×107
+ + + + 1.73×107
+ + + - 2.80×108
+ + + + 2.21×107
+ + + - 9.63×108
+ + + - 6.98×107
+ + + - 2.94×107
+ + + - 7.82×107
+ + + - 2.24×107
+ + + - 1.15×107
+ + + - 3.77×107
+ + + - 6.42×107
Table 4 HBV Genotypes among 165 pregnant women
Group Genotype B Genotype C
Infants with HBV infection 2 10
n=12




χ2 =3.96, P< 0.05.
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HBV mother-to-child transmission can be prevented by
the administration of immunoprophylaxis with HBIG and
the hepatitis B vaccine [8,9]. It has been confirmed that
the failure of immunoprophylaxis is mainly associated
with maternal seropositivity for HBeAg and high viral load
[10-12]. It is recommended that HBsAg-positive pregnant
women who are HBeAg positive and have a high viral load
be given antivirals in late pregnancy to suppress virema
[13-15]. Thus, it is important to survey chronic HBV
infection among pregnant women and their infants and
find other reasons for immunoprophylaxis failure.
There were a total of 4,536 pregnant women aged 16 –
45 years who were enrolled in our study. We showed that
the prevalence of HBsAg among pregnant women in
Shenyang was 5.49%, which is lower than the overall
prevalence of HBsAg among pregnant women in China
(8.16%) [16]. The prevalence of HBsAg, anti-HBc and
anti-HBs among pregnant women older than 20 years of
age was 4.54, 5.69 and 0.61 times that among pregnant
women younger than 20 years, respectively. The difference
in prevalence of HBsAg, anti-HBc and anti-HBs between
pregnant women older than 20 years versus younger than
20 years of age was significant. This could be related to
immunoprophylaxis having been universally administered
to infants since 1990, which could improve immunity
against HBV and decrease HBV infection among their
infants.
Among HBsAg positive pregnant women, the majority
were HBeAg positive and HBVDNA positive (67.07% and
81.93%, respectively), a minority (14.86%) had a high viral
load. Only 12 (4.82%) infants were HBsAg and HBVDNA
positive, and their mothers were also HBeAg positive and
had HBVDNA>107 IU/ml, which confirmed previous
reports. These HBeAg positive and high viral load pregnant
women should be offered antiviral treatment during late
pregnancy to prevent HBV mother-to-child transmission.
There were 2 infants who were both anti-HBs and HBsAg
positive. It was reported that the infants were infected with
mutant strains which were transmitted from their mothers
[17-20]. We should further test sequence analysis to sup-
port it and manufacture mutant strain vaccines to prevent
HBV mother-to-child transmission.HBV has been classified into eight genotypes, desig-
nated as A-H, based on intergenotypic divergence of at
least 8% in the complete nucleotide sequence or more
than 4% in the S gene [21-27]. HBV genotypes have dis-
tinct geographical distributions and correlate with the
severity of liver diseases [28-30]. Are HBV genotypes of
great importance in HBV mother-to-child transmission
and/or affect the immunization success with HBIG and
hepatitis B vaccine? Only genotypes B and C were found
among 165 pregnant women. There was a significant dif-
ference in genotypes between the pregnant women
whose infants were HBV infected and those without
HBV infection. Genotype C might be a risk factor for
HBV mother to child transmission. It should be recom-
mended that pregnant women who are HBeAg positive
and have a high viral load be tested for HBV genotypes.
Conclusions
There was a significant decline in the HBsAg prevalence
among pregnant women and their infants in Shenyang,
which might be attributed to universal implementation
of immunoprophylaxis since 1990. Genotype C might be
a risk factor for HBV mother to child transmission.
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